Public and private M&A
William Hill plc
Advised on the £485 million recommended offer for Sportingbet, by way of joint consortium bid by William Hill and GVC, together with related acquisition of Spanish assets.
URS Corporation (NYSE-listed)
Advised on its £161 million offer for Scott Wilson Group plc.
Ark Therapeutics
Advised on a number of bid approaches, and formal sale process.
Other public takeovers include NeuTec Pharma, Quadrant Healthcare, Enodis, RHM, Debenhams, QXL Ricardo, Linx and Carluccio's.
Snap-on Inc.
Advised Snap-on on its $72 million acquisition of Norbar Torque Tools, and separately its acquisition of BTC Global.
Bell Pottinger (in administration)
Acted for BDO LLP as administrators on the sale of both the Far East and Middle East businesses of Bell Pottinger (in administration).
Silence Therapeutics plc
Advised on its acquisition of Palo Alto-based Intradigm Corporation, comprising a reverse takeover under the AiM Rules with a Rule 9 whitewash together with a £15 million equity fundraising through a placing and subscription to corporate investors and major pharmaceutical companies.
Ark Therapeutics
Advised on the disposal of its operating business to a vehicle financed by Wolbern Private Equity.
Healthcare at Home
Advised its management and certain shareholders on the disposal of the Healthcare at Home Group to Hutton Collins, and subsequent disposal to Vitruvian Partners' vehicle Halcyon Acquisitions.
Ark Therapeutics
Advised on the sale of its woundcare products division to Crawford Healthcare.
Arakis Limited and its shareholders
Advised on the acquisition of Arakis by Sosei Co. Ltd., a leading Japanese biopharmaceutical company.
Quadrant Technologies Limited
Advised the vendors on its £46.7 million sale to ML Laboratories plc.
Mölnlycke Health Care
Advised on their twin track exit, a process which concluded in the sale of Mölnlycke to Investor AB and Morgan Stanley Principal Investment for €2.85 billion.
More: Public and private M&A
Equity capital markets
Acacia Pharma Group plc
Advised Acacia Pharma on its €190 million IPO on Euronext Brussels.
William Hill plc
Advised on its £1.2 billion funding proposals, comprising new and existing bank facilities of £840 million and a £350 million rights issue underwritten by Citi, RBS Hoare Govett and Barclays.
William Hill plc
Advised on a £375 million 2 for 9 rights issue, underwritten by Citi, Investec and Barclays.
Imperial College London of Science, Technology and Medicine as a major shareholder of Imperial Innovations Group plc (Innovations)
Advised on a £140 million rights issue and issue of warrants by Innovations, sponsored by JP Morgan Cazenove.
CPP Group plc
Advised on its main market London IPO including a global offer of £30 million new shares, underwritten by JP Morgan Cazenove and UBS.
Cambian Group plc
Advised on its main market London IPO, underwritten by JP Morgan Cazenove.
NM Rothschild, RBS Hoare Govett and Oriel Securities as the sponsor and underwriters
Advised on a £114 million placing and rights issue by Northgate plc.
NM Rothschild, Oriel Securities and KBC Peel Hunt as the sponsor and underwriters
Advised on a £105 million rights issue by Speedy Hire Plc.
NM Rothschild, JP Morgan Cazenove and Peel Hunt as the sponsor and joint bookrunners
Advised on a Class 2 acquisition and related placing by Vectura plc.
Other IPOs include Quadrant Healthcare, Ark Therapeutics, Inion Oy, RHM, PV Crystalox Solar, Silverjet and Anker.
More: Equity capital markets
Private equity and venture capital
Titan Cement
Advised this cement and building materials producer listed on the Athens Stock Exchange in respect of a €50 million equity investment by International Finance Corporation (IFC) in Titan's operations in the Former Yugoslav Republic of Macedonia, Serbia and Kosovo, on the equity and debt financing by IFC and EBRD of a €147 million greenfield cement plant in Albania and subsequent €27 million follow-on investment.
Acacia Pharma Limited
Advised this pharmaceutical company specialising in the development of drugs for cancer and post-operative supportive care on its Series A, B and C investment rounds, with cornerstone investments from Gilde, Novo, Lundbeck and Fidelity Biosciences (F-Prime).
Quadrant Technologies Limited
Advised the management on the buy-out from Elan Corporation, plc of the UK-based drug delivery business Elan Drug Delivery Limited.
Jane Shepherdson
Advised Jane and the incoming management team on their equity investment in clothing retailer Whistles.
Arakis Limited
Advised on a £29 million private funding round.
More: Private equity and venture capital